230 related articles for article (PubMed ID: 33879260)
21. Implementation of emergency department-initiated buprenorphine for opioid use disorder in a rural southern state.
Bogan C; Jennings L; Haynes L; Barth K; Moreland A; Oros M; Goldsby S; Lane S; Funcell C; Brady K
J Subst Abuse Treat; 2020 Mar; 112S():73-78. PubMed ID: 32220414
[TBL] [Abstract][Full Text] [Related]
22. Syringe service program-based telemedicine linkage to opioid use disorder treatment: protocol for the STAMINA randomized control trial.
Watson DP; Swartz JA; Robison-Taylor L; Mackesy-Amiti ME; Erwin K; Gastala N; Jimenez AD; Staton MD; Messmer S
BMC Public Health; 2021 Mar; 21(1):630. PubMed ID: 33789642
[TBL] [Abstract][Full Text] [Related]
23. Availability of Medications for the Treatment of Opioid Use Disorder Among Pregnant and Postpartum Individuals in US Jails.
Sufrin C; Kramer CT; Terplan M; Fiscella K; Olson S; Voegtline K; Latkin C
JAMA Netw Open; 2022 Jan; 5(1):e2144369. PubMed ID: 35050354
[TBL] [Abstract][Full Text] [Related]
24. Telehealth in opioid use disorder treatment: policy considerations for expanding access to care.
Niyibizi A; Haveric A; Irio G
J Osteopath Med; 2024 Apr; 124(4):179-181. PubMed ID: 37976470
[TBL] [Abstract][Full Text] [Related]
25. Treatment of opioid use disorder during COVID-19: Experiences of clinicians transitioning to telemedicine.
Uscher-Pines L; Sousa J; Raja P; Mehrotra A; Barnett M; Huskamp HA
J Subst Abuse Treat; 2020 Nov; 118():108124. PubMed ID: 32893047
[TBL] [Abstract][Full Text] [Related]
26. Prior National Drug Abuse Treatment Clinical Trials Network (CTN) opioid use disorder trials as background and rationale for NIDA CTN-0100 "optimizing retention, duration and discontinuation strategies for opioid use disorder pharmacotherapy (RDD)".
Shulman M; Weiss R; Rotrosen J; Novo P; Costello E; Nunes EV
Addict Sci Clin Pract; 2021 Mar; 16(1):15. PubMed ID: 33676577
[TBL] [Abstract][Full Text] [Related]
27. Medication treatment for opioid use disorder and community pharmacy: Expanding care during a national epidemic and global pandemic.
Cochran G; Bruneau J; Cox N; Gordon AJ
Subst Abus; 2020; 41(3):269-274. PubMed ID: 32697171
[TBL] [Abstract][Full Text] [Related]
28. Exemplar Hospital initiation trial to Enhance Treatment Engagement (EXHIT ENTRE): protocol for CTN-0098B a randomized implementation study to support hospitals in caring for patients with opioid use disorder.
Bart G; Korthuis PT; Donohue JM; Hagedorn HJ; Gustafson DH; Bazzi AR; Enns E; McNeely J; Ghitza UE; Magane KM; Baukol P; Vena A; Harris J; Voronca D; Saitz R
Addict Sci Clin Pract; 2024 Apr; 19(1):29. PubMed ID: 38600571
[TBL] [Abstract][Full Text] [Related]
29. Response to coronavirus 2019 in Veterans Health Administration facilities participating in an implementation initiative to enhance access to medication for opioid use disorder.
Gustavson AM; Gordon AJ; Kenny ME; McHenry H; Gronek J; Ackland PE; Hagedorn HJ
Subst Abus; 2020; 41(4):413-418. PubMed ID: 32936695
[TBL] [Abstract][Full Text] [Related]
30. An ethical analysis of medication treatment for opioid use disorder (MOUD) for persons who are incarcerated.
Brezel ER; Powell T; Fox AD
Subst Abus; 2020; 41(2):150-154. PubMed ID: 31800376
[TBL] [Abstract][Full Text] [Related]
31. Factors associated with receipt of medication for opioid use disorder among pregnant individuals entering treatment programs in the U.S.
Curran L; Manuel J
Int J Drug Policy; 2024 Apr; 126():104342. PubMed ID: 38479161
[TBL] [Abstract][Full Text] [Related]
32. The impact of COVID-19 and rapid policy exemptions expanding on access to medication for opioid use disorder (MOUD): A nationwide Veterans Health Administration cohort study.
Livingston NA; Davenport M; Head M; Henke R; LeBeau LS; Gibson TB; Banducci AN; Sarpong A; Jayanthi S; Roth C; Camacho-Cook J; Meng F; Hyde J; Mulvaney-Day N; White M; Chen DC; Stein MD; Weisberg R
Drug Alcohol Depend; 2022 Dec; 241():109678. PubMed ID: 36368167
[TBL] [Abstract][Full Text] [Related]
33. Access to Medications for Opioid Use Disorder in Rural Versus Urban Veterans Health Administration Facilities.
Wyse JJ; Shull S; Lindner S; Morasco BJ; Gordon AJ; Carlson KF; Korthuis PT; Ono SS; Liberto JG; Lovejoy TI
J Gen Intern Med; 2023 Jun; 38(8):1871-1876. PubMed ID: 36690913
[TBL] [Abstract][Full Text] [Related]
34. The COVID-19 pandemic and opioid use disorder: Expanding treatment with buprenorphine, and combining safety precautions with telehealth.
Cales RH; Cales SC; Shreffler J; Huecker MR
J Subst Abuse Treat; 2022 Feb; 133():108543. PubMed ID: 34210567
[TBL] [Abstract][Full Text] [Related]
35. Test of a workforce development intervention to expand opioid use disorder treatment pharmacotherapy prescribers: protocol for a cluster randomized trial.
Molfenter T; Knudsen HK; Brown R; Jacobson N; Horst J; Van Etten M; Kim JS; Haram E; Collier E; Starr S; Toy A; Madden L
Implement Sci; 2017 Nov; 12(1):135. PubMed ID: 29141653
[TBL] [Abstract][Full Text] [Related]
36. Massachusetts Justice Community Opioid Innovation Network (MassJCOIN).
Evans EA; Stopka TJ; Pivovarova E; Murphy SM; Taxman FS; Ferguson WJ; Bernson D; Santelices C; McCollister KE; Hoskinson R; Lincoln T; Friedmann PD;
J Subst Abuse Treat; 2021 Sep; 128():108275. PubMed ID: 33483222
[TBL] [Abstract][Full Text] [Related]
37. Medications for opioid use disorder in state prisons: Perspectives of formerly incarcerated persons.
Treitler PC; Enich M; Reeves D; Crystal S
Subst Abus; 2022; 43(1):964-971. PubMed ID: 35420973
[No Abstract] [Full Text] [Related]
38. Access to medication for opioid use disorder supported by telemedicine and healthcare coverage: A web-based survey during the COVID-19 pandemic.
Monnig MA; Clark SE; Treloar Padovano H; Sokolovsky AW; Goodyear K; Ahluwalia JS; Monti PM
Addict Behav Rep; 2023 Dec; 18():100515. PubMed ID: 37731991
[TBL] [Abstract][Full Text] [Related]
39. Improving methadone access for rural communities in the USA: lessons learned from COVID-19 adaptations and international models of care.
Lister JJ; Lister HH
Rural Remote Health; 2021 Nov; 21(4):6770. PubMed ID: 34757760
[TBL] [Abstract][Full Text] [Related]
40. Multidimensional assessment of access to medications for opioid use disorder across urban and rural communities: A scoping review.
Bommersbach T; Justen M; Bunting AM; Funaro MC; Winstanley EL; Joudrey PJ
Int J Drug Policy; 2023 Feb; 112():103931. PubMed ID: 36563489
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
